Immediate response
Growth-hormone release follows administration within the pulse window.
Protocol / Research Dosing Guide
Ipamorelin Dosage Guide: Reported Schedule, Reconstitution and Safety
A source-gated Ipamorelin reference covering the community-derived schedule, vial arithmetic and the boundary where published evidence stops.
Last reviewed September 16, 202618 minute readResearch information only
Level 2 — Pharmacology and early human researchNo trial for the marketed usesNot FDA approved
Ipamorelin Quick Start
Ipamorelin is a pentapeptide growth-hormone secretagogue known for releasing growth hormone without meaningfully raising cortisol or prolactin. Published human work used other routes and formulations for different endpoints. No human trial has tested ipamorelin for growth-hormone optimization, body composition or anti-aging outcomes, so the schedule below is community-derived.
Why researchers care
Growth-hormone pulse research, body composition and recovery discussion
Class
Selective growth-hormone secretagogue acting at the ghrelin (GHS-R1a) receptor
Route reported
Subcutaneous after reconstitution
Cycle length
Community reported 8–12 weeks on, 4 weeks off
Regulatory status
Not FDA approved
Loading supplier information
Ipamorelin Dosing Protocol and Schedule
The supplied source reports a titration from 100 mcg per day in week one to 200–300 mcg per day through weeks four to twelve, one to three administrations daily, then a four-week off period. It states plainly that this is community-derived rather than trial-derived.
| Phase or study | Amount | Frequency / evidence |
|---|---|---|
| Week 1 | 100 mcg per day, once at bedtime, fasted | Community reported titration |
| Weeks 2–3 | 200 mcg per day, once at bedtime or split morning and evening | Community reported |
| Weeks 4–8 | 200–300 mcg per day, one to two administrations | Community reported |
| Weeks 9–12 | 200–300 mcg per day, continued if tolerated | Community reported |
| Off cycle | 4 weeks at zero | Community reported |
No human trial has validated these amounts, this titration, the block length or the off period. Reported practice describes roughly 300 mcg per administration as a practical ceiling because the growth-hormone response is said to flatten above it.
Ipamorelin Supplies Needed
Neutral research-material planning only. This does not establish an appropriate amount or route.
Research planning item
Exact labeled research vial
Research planning item
Bacteriostatic water, roughly 3 mL per 10 mg vial in the source example
Research planning item
U-100 insulin syringes, 0.3 mL barrel preferred for small draws
Research planning item
Alcohol prep swabs
Research planning item
Sharps container
Research planning item
Refrigeration for the prepared vial
Research planning item
Written concentration label
Ipamorelin Reconstitution Calculator
Vial-format concentration math
Concentration
3.333 mg/mL
Draw volume
0.06 mL
U-100 units
6
Mathematical draws
50
Arithmetic only. The entered amount is not a recommendation and does not establish suitability.
Best Time to Take Ipamorelin: Morning or Night?
Bedtime or morning?
Community practice favors bedtime because growth hormone surges during deep sleep.
Fasted?
Reported practice describes an empty stomach, commonly one to two hours after food and twenty to thirty minutes before eating, because insulin blunts the growth-hormone pulse.
Once or split?
One to three administrations per day appear in reported schedules; three is described as the maximum.
Missed amount?
Reported practice resumes at the next scheduled time rather than doubling.
Ipamorelin Route Comparison
| Format | What is reported | Evidence limit |
|---|---|---|
| Subcutaneous | The route used in community schedules | No trial for these endpoints |
| Intravenous (published studies) | Used in published human pharmacology | Different route and formulation; do not transfer the schedule |
| Oral | Not viable | Digestion degrades the peptide |
Routes and amounts are not interchangeable unless a verified study explicitly establishes a conversion.
Ipamorelin Half-Life and Dosing Frequency
| Measure | Finding | Evidence limit |
|---|---|---|
| Reported half-life | About two hours | Published pharmacology |
| Why frequency varies | The short half-life is the reason schedules range from one to three administrations daily | Reported rationale |
| Pulse coverage | One administration gives one clean pulse; two or three extend coverage | Reported rationale |
| Duration of effect | Not established for the community endpoints | No trial |
Ipamorelin Dosage Chart
| Route | Amount | Frequency | Source | Human validation |
|---|---|---|---|---|
| Subcutaneous | 100 mcg | Once daily | Community report | No |
| Subcutaneous | 100 mcg | Twice daily (200 mcg per day) | Community report | No |
| Subcutaneous | 200 mcg | Once daily | Community report | No |
| Subcutaneous | 300 mcg | Up to three times daily (900 mcg per day) | Community report | No |
Published study values describe those studies. Community-reported values are not validated dosing recommendations.
Ipamorelin Reconstitution Guide
Concentration: 3.333 mg/mL
| Entered amount | Volume | U-100 units |
|---|---|---|
| 0.2 mg | 0.06 mL | 6 units |
| 0.4 mg | 0.12 mL | 12 units |
| 0.6 mg | 0.18 mL | 18 units |
- 1.Confirm the milligram total on the vial label.
- 2.Record the exact bacteriostatic water volume added.
- 3.Clean the stopper with an alcohol swab.
- 4.Add liquid slowly down the vial wall.
- 5.Swirl gently until clear; do not shake.
- 6.A 2 mg vial with 1.0 mL gives 2,000 mcg/mL; a 5 mg vial with 2.0 mL gives 2,500 mcg/mL; a 10 mg vial with 3.0 mL gives about 3,333 mcg/mL.
- 7.At 3,333 mcg/mL, 100 mcg is 3 units, 200 mcg is 6 units and 300 mcg is 9 units on a U-100 syringe.
- 8.Label the concentration and preparation date, then refrigerate.
Reconstitution does not establish identity, purity, sterility, stability, or an appropriate amount.
How Ipamorelin Works
Receptor target
Ipamorelin is a selective agonist at the ghrelin receptor, GHS-R1a.
Ipamorelin Human Trials and FDA Status
Current status · verified September 16, 2026
Not FDA approved
- Published human work used different routes and formulations for endpoints such as post-operative ileus, not growth-hormone optimization.
- No human trial has tested subcutaneous ipamorelin for body composition, anti-aging or recovery endpoints.
- Ipamorelin was not brought to market as a medicine and is not FDA approved.
- The cycle lengths described in communities have never been validated, and no study shows that an off period preserves receptor responsiveness.
Who Should Avoid Ipamorelin?
This is an evidence-gap and precaution list, not an approved prescribing label.
Active or prior cancer
Growth-hormone axis stimulation is not evaluated for safety in this setting
Pregnancy or breastfeeding
No safety data
Children or adolescents
Growth-axis effects are not characterized for this use
Diabetes or impaired glucose tolerance
Growth hormone can reduce insulin sensitivity
Untreated endocrine disease
Requires diagnosis and clinical management first
Ipamorelin Side Effects, Risks and Safety
Injection-site reactionAnecdotal
Important limitation: No controlled incidence data.
Headache or light-headednessAnecdotal
Important limitation: Commonly reported after administration.
Water retention or joint discomfortAnecdotal
Important limitation: Consistent with growth-hormone effects but not quantified.
Increased hungerAnecdotal
Important limitation: Ghrelin-receptor activity makes this mechanistically plausible.
Glucose changesMechanistic
Important limitation: Growth hormone can reduce insulin sensitivity.
Long-term effectsUnknown
Important limitation: No follow-up evidence.
Ipamorelin Timeline and Monitoring
Reported subjective changes
Sleep and recovery reports appear within weeks in community accounts; these are anecdotal.
Block structure
Eight to twelve weeks on, four weeks off, per reported practice.
Monitoring
No validated monitoring schedule exists; IGF-1 testing is discussed in communities without trial support.
Ipamorelin Benefits and Results: What the Evidence Shows
| Claim | Evidence level | What research shows | Important limitation |
|---|---|---|---|
| Growth-hormone release | Established pharmacology | Level 2 | Not an outcome claim |
| Body composition | Not established | Community reported | No human trial |
| Sleep quality | Not established | Anecdotal | No controlled data |
| Recovery | Not established | Anecdotal | No controlled data |
Ipamorelin Storage and Handling
Unreconstituted vial
Follow the product label; keep cool, dry and out of light.
Prepared vial
Refrigerate and protect from light; follow the product label for the use window.
Freezing
Repeated freeze-thaw cycles are avoided for peptide solutions.
Appearance
Cloudiness, discoloration or particles mean the solution should not be used.
Ipamorelin Troubleshooting
Units differ from a reference table
Concentration depends on the liquid volume you added; recompute from your own vial.
Strong hunger after administration
Mechanistically consistent with ghrelin-receptor activity; it is not a validated dosing signal.
Solution appears cloudy
Stop and seek qualified product guidance.
A scheduled administration is missed
Reported practice resumes at the next scheduled time without doubling.
Unexpected symptoms
Seek licensed clinical review; no validated safety protocol exists.
Ipamorelin Comparisons
| Compound | Class or mechanism | Evidence | FDA status |
|---|---|---|---|
| Ipamorelin | Selective GHS-R1a agonist | Minimal cortisol and prolactin rise reported | Not approved |
| CJC-1295 without DAC | GHRH analogue | Different receptor and pulse profile | Not approved |
| MK-677 | Orally active secretagogue | Longer exposure and different side-effect profile | Not approved |
Ipamorelin Frequently Asked Questions
What is ipamorelin?
A pentapeptide growth-hormone secretagogue acting at the ghrelin receptor.
Is ipamorelin FDA approved?
No.
Is the 8–12 week cycle validated?
No. It is community-derived.
What is its half-life?
About two hours in published pharmacology.
Why is bedtime common?
Growth hormone naturally surges during deep sleep, and food raises insulin, which blunts the pulse.
Is there a ceiling amount?
Reported practice describes about 300 mcg per administration as the practical ceiling before side effects rise without more growth hormone.
Do men and women use different amounts?
No sex-specific amount is established; some community sources describe 100–200 mcg per administration for women, which already sits inside the general range.
What does a 10 mg vial with 3 mL give?
About 3,333 mcg/mL, so 200 mcg is 6 units on a U-100 syringe.
How long does a 10 mg vial last?
At 200 mcg per day it covers roughly 50 administrations before priming losses.
Does ipamorelin raise cortisol?
It is characterized as selective, with minimal cortisol and prolactin effect compared with older secretagogues.
What does the calculator do?
Concentration and volume arithmetic only.
Sources and Research
Coverage source
1. Ipamorelin protocol coverage source
Supplied coverage source for the community schedule, supply planning and vial arithmetic.
Open direct sourcePublished pharmacology
2. Ipamorelin, the first selective growth hormone secretagogue
Original pharmacology describing selectivity and growth-hormone release.
Open direct sourcePublished research
3. Growth hormone secretagogue receptor (GHS-R1a) pharmacology
Receptor-level context for secretagogue activity.
Open direct sourceMissing information flagged for review
- Human trial for body-composition or anti-aging endpoints: Not established
- Validated cycle and rest period: Not established
- Sex-specific amounts: Not established
- Long-term safety data: Not established
- Validated monitoring schedule: Not established